Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by River Road Asset Management LLC

River Road Asset Management LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 9.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 469,980 shares of the biopharmaceutical company’s stock after purchasing an additional 41,918 shares during the quarter. River Road Asset Management LLC’s holdings in Royalty Pharma were worth $13,296,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Xponance Inc. grew its stake in shares of Royalty Pharma by 1.9% during the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after purchasing an additional 606 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares in the last quarter. Values First Advisors Inc. lifted its position in shares of Royalty Pharma by 7.6% during the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 738 shares in the last quarter. Phillips Wealth Planners LLC lifted its position in shares of Royalty Pharma by 10.2% during the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 808 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Royalty Pharma by 10.8% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 887 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday. Morgan Stanley increased their target price on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, The Goldman Sachs Group raised their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has an average rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Trading Up 1.3 %

Shares of RPRX stock opened at $27.54 on Wednesday. The stock’s fifty day moving average is $27.95 and its two-hundred day moving average is $27.56. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The firm has a market capitalization of $16.34 billion, a P/E ratio of 24.37, a PEG ratio of 3.99 and a beta of 0.47. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The business had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same period last year, the company earned $0.85 EPS. Research analysts expect that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 74.34%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.